Cleerly, the company creating a new standard of care for heart disease, announced that it has closed a Series C financing round of $192 million. The oversubscribed funding round was led by funds and accounts advised by T. Rowe Price Associates, Inc. and T. Rowe Price Investment Management, Inc., and Fidelity Management and Research Company. Cleerly’s existing investors participated in the financing and include Vensana Capital, LRVHealth, New Leaf Ventures, Cigna Ventures and DigiTx Partners.
Cigna Ventures | Health Care Venture Capital
Footer
By contacting The Cigna Group Ventures through this website, you agree and acknowledge that information you submit will not be considered or treated as confidential or proprietary unless and until a separate agreement is signed and that The Cigna Group Ventures and its affiliates are under no obligation to review your submission or to enter into any agreement, investment or transaction associated with the submission. In no event will The Cigna Group Ventures or any of its affiliates be limited in, or restricted from, the pursuit of any opportunities, either alone or with third parties.
The information contained herein does not constitute a distribution, an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction in which such distribution or offer is not authorized. In particular, the information herein is not for distribution and does not constitute an offer to sell or the solicitation of any offer to buy any securities in the United States (U.S.) or for the benefit of any U.S. person (being residents of the United States or partnerships or corporations organized under the laws of the United States), nor in any other country.